anthracycline

patients were treated with an anthracycline-based chemotherapy regimen.

doxorubicin is a widely used anthracycline antibiotic.

clinical guidelines recommend anthracycline therapy for this cancer type.

the patient developed anthracycline-induced cardiotoxicity during treatment.

doctors must monitor the cumulative anthracycline dose carefully.

researchers are developing new anthracycline analogues with fewer side effects.

resistance to anthracycline drugs remains a major clinical challenge.

the study compared the efficacy of taxane and anthracycline combinations.

dexrazoxane is used to protect the heart during anthracycline administration.

anthracycline extravasation can cause severe tissue necrosis.

biomarkers are needed to predict anthracycline response in patients.

advancements in liposomal anthracycline delivery have improved safety profiles.